PD43-07 SACRAL NEUROMODULATION DEVICE BIOFILMS DIFFER IN COMPOSITION BY INFECTION STATUS AND TESTING PHASE

Le résumé fourni par la source

You have accessJournal of UrologyUrodynamics/Lower Urinary Tract Dysfunction/Female Pelvic Medicine: Overactive Bladder I (PD43)1 May 2024PD43-07 SACRAL NEUROMODULATION DEVICE BIOFILMS DIFFER IN COMPOSITION BY INFECTION STATUS AND TESTING PHASE Glenn Werneburg, Daniel Hettel, Sandip Vasavada, Howard Goldman, Ava Adler, Bradley Gill, Raymond Rackley, Jacqueline Zillioux, Sarah Martin, Sromona Mukherjee, Daniel Shoskes, and Aaron Miller Glenn WerneburgGlenn Werneburg , Daniel HettelDaniel Hettel , Sandip VasavadaSandip Vasavada , Howard GoldmanHoward Goldman , Ava AdlerAva Adler , Bradley GillBradley Gill , Raymond RackleyRaymond Rackley , Jacqueline ZilliouxJacqueline Zillioux , Sarah MartinSarah Martin , Sromona MukherjeeSromona Mukherjee , Daniel ShoskesDaniel Shoskes , and Aaron MillerAaron Miller View All Author Informationhttps://doi.org/10.1097/01.JU.0001009568.19060.25.07AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: Sacral neuromodulation (SNM) is effective for urinary retention and medically-refractory overactive bladder. A subset of implanted SNM devices is associated with infection requiring surgical removal. We aimed to compare microbial compositions of SNM device biofilms in the presence and absence of infection and other clinical factors. We hypothesized that SNM devices would have significantly different biofilm composition by infection status and testing phase prior to initial device placement. METHODS: Urological patients scheduled to undergo removal of SNM devices were consented per IRB-approved protocol. Devices were swabbed intraoperatively upon exposure during explantation. Samples and controls were analyzed using next-generation sequencing. Associations between microbial diversity and microbial abundance, and clinical variables were then analyzed using t-tests and ANOVA. RESULTS: 37 devices were analyzed. Biofilms were consistently detected even in the absence of infection, and microbial beta diversity differed in the presence versus absence of infection (p=0.01, Figure panel A). Proteobacteria, Firmicutes, and Actinobacteriota were the most common phyla present. There were lower microbial counts in biofilms from sacral neuromodulation devices that were implanted following percutaneous nerve evaluation (PNE) versus a stage 1 testing phase (p<0.001, Figure panel B). CONCLUSIONS: SNM device biofilms harbored unique microbiota in the presence and absence of infection. There were lower microbial counts detected in device biofilms from devices that were initially implanted following a PNE versus a stage 1 testing phase. The findings open new avenues for investigation of the pathophysiological transition of a medical device from a colonized asymptomatic state to an infected state, and identify preventative strategies. Download PPT Source of Funding: SUFU Foundation Neuromodulation Award © 2024 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 211Issue 5SMay 2024Page: e901 Advertisement Copyright & Permissions© 2024 by American Urological Association Education and Research, Inc.Metrics Author Information Glenn Werneburg More articles by this author Daniel Hettel More articles by this author Sandip Vasavada More articles by this author Howard Goldman More articles by this author Ava Adler More articles by this author Bradley Gill More articles by this author Raymond Rackley More articles by this author Jacqueline Zillioux More articles by this author Sarah Martin More articles by this author Sromona Mukherjee More articles by this author Daniel Shoskes More articles by this author Aaron Miller More articles by this author Expand All Advertisement PDF downloadLoading ...

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.